(162 days)
No
The description focuses on hardware components, control systems based on ventilator waveforms and user settings, and safety mechanisms. There is no mention of learning, adaptation, or complex pattern recognition characteristic of AI/ML.
Yes
The device delivers INOmax (nitric oxide) therapy gas, which is a treatment for patients.
No
This device is designed to deliver therapy gas and monitor the delivered gas levels (O2, NO2, NO) to ensure safe and effective delivery of the treatment. It does not perform a diagnostic function to identify or characterize a disease or condition.
No
The device description clearly outlines numerous hardware components including a delivery CPU, flow controller, injector module, monitoring system with a separate monitor CPU, gas cells, user interface with display and alarms, battery, high pressure regulator, tubing, quick connect inlets, filter, safety shutoff valve, proportional solenoid, flow sensor, check valve, water trap, zero valve, sample pump, sample flow sensor, electrochemical gas monitoring cells, pneumatic on/off switch, and restrictor. This is not a software-only device.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The INOmax DS delivery system delivers a therapeutic gas (nitric oxide) into the patient's breathing circuit. It also monitors gases within the breathing circuit (inspired O2, NO2, and NO).
- No Sample Analysis: The device does not analyze samples taken from the patient's body. Its monitoring function is focused on the gas composition being delivered and inhaled, not on biological samples.
Therefore, the INOmax DS is a therapeutic and monitoring device used in the delivery of a drug, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The INOmax DS delivery system delivers INOmax® (nitric oxide of inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. It uses a specially designed injector module, which enables tracking of the ventilator wayeforms and the delivery of a synchronized and proportional dose of NO. It may be used with most ventilators.
The INOmax DS provides continuous integrated monitoring of inspired O2, NO2, and NO, and a comprehensive alarm system.
The INOmax DS incorporates a battery that provides up to 6 hours of uninterrupted NO delivery in the absence of an external power source.
The INOmax DS includes a backup NO delivery capability that provides a fixed flow of 250 mL/min of NO which along with user supplied 10 L/min of oxygen provides 20 ppm in the gas flow to a patients breathing circuit. It may also use the INOblender for backup.
Product codes
MRN, MRO, MRP and MRQ
Device Description
The INOmax DS provides a constant dose of INOmax (nitric oxide) therapy gas into the inspiratory limb of the ventilator circuit. The INOmax DS uses a "dual-channel" design to ensure the safe delivery of INOmax. The first channel has the delivery CPU, the flow controller and the injector module to ensure the accurate delivery of NO. The second channel is the monitoring system, which includes a separate monitor CPU, the gas cells (NO, NO2, and O2 cells) and the user interface including the display and alarms. The dual-channel approach to delivery and monitoring permits INOmax delivery independent of monitoring but also allows the monitoring system to shutdown INOmax delivery if it detects a fault in the delivery system such that the NO concentration could become greater than 100 ppm. INOmax drug is stored as a gas mixture of NO/N2 in an aluminum cylinder at a nominal pressure of 2200 psig. The cylinder is attached to a high pressure regulator which incorporates a pressure gauge that indicates cylinder pressure when the cylinder valve is open. The cylinder regulator is attached via tubing to the INOmax DS using one of the two NO/N2 quick connect inlets on the back of the machine. The INOmax enters the back of the INOmax DS, passes through a filter. then a safety shutoff valve, which is open under normal operation. An injector module is placed in the ventilator gas flow between the ventilator inspiratory outlet and the humidifier. Based on the ventilator flow, the INOmax cylinder concentration and set INOmax dose, the proportional solenoid delivers INOmax into the ventilator circuit via the injector module. This allows the INOmax DS to deliver a constant dose of INOmax regardless of the ventilator flow pattern or breath rate. A flow sensor inside the INOmax DS also monitors the NO flow out of the machine. A check valve is included prior to the INOmax DS drug outlet to prevent pressure effects from the ventilator breathing circuit interfering with the NO flow sensor reading. The INOmax DS gas monitoring system provides monitored values for inspired NO, NO2, and O2. The sample gas is withdrawn form the breathing circuit and goes through a water trap to remove excess water, a zero valve, a sample pump and finally a sample flow sensor to the gas monitoring cells. The zero valve allows the gas cells to be zeroed (during low calibration) without having to disconnect the sample line from the breathing circuit. The pump and sample flow sensor ensure a constant sample gas flow rate is maintained to the monitoring cells. The gas monitoring cells are electrochemical; they are specific to each gas and provide an electronic signal, which is proportional to the concentration of the gas present. If the delivery system does go into shut down, the INOmax DS has an integrated backup function which provides a fixed flow of INOmax (0.25L/min) into the injector module using a pneumatic on/off switch and a restrictor built into the delivery side of the system. This fixed flow of INOmax will provide 20 ppm of NO when the continuous ventilator gas flow is 10 L/min. The backup is only for short term use until a replacement delivery system can be obtained. An alarm will warn the user if the backup system is turned on while the main delivery system is in use for INOmax delivery.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
neonates
Intended User / Care Setting
Primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU) and secondary targeted clinical setting is the transport of neonates.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance bench testing
Integrity testing
Environmental and mechanical testing
Validation against ventilators testing
Product standards certification testing
Key results: The INOmax DS met its design input specifications, design output specifications and risk analysis requirements and is safe and effective for its indicated uses. The device is as safe and effective as the predicate INOvent Delivery System, while performing as well or better than this predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Ohmeda INOvent Delivery System (now GE Healthcare) 510(k) Number K974562, Datex-Ohmeda INOvent Delivery System (now GE Healthcare) 510(k) Number K000186, INO Therapeutics INOblender 510(k) Number K052663, Pulmonox Vianox Delivery System (now SensorMedics) 510(k) Number K023014, Pulmonox Aeronox Delivery System (now SensorMedics) 510(k) Number K000653
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 868.5165 Nitric oxide administration apparatus.
(a)
Identification. The nitric oxide administration apparatus is a device used to add nitric oxide to gases that are to be breathed by a patient. The nitric oxide administration apparatus is to be used in conjunction with a ventilator or other breathing gas administration system.(b)
Classification. Class II. The special control for this device is FDA's “Guidance Document for Premarket Notification Submissions for Nitric Oxide Administration Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer.”
0
K 061901
Image /page/0/Picture/1 description: The image shows the logo for INC Therapeutics. The letters "INC" are in bold, black font, with the "C" partially encircling the word "Therapeutics." The word "Therapeutics" is in a smaller, black font and is underlined.
7601-B Murphy Drive
Middleton, WI 53562 USA Tel. 608-831-4401 / Fax. 608-831-4409 DEC 1 4 2006
| Date: | September 18, 2006 |
|---|---|
| Contact Person: | Frederick Montgomery, Vice President, Medical Devices |
| Subject: | 510(k) Summary of Safety and Effectiveness Information for the |
| INO Therapeutics INOmax DS. This summary of safety and effectiveness | |
| information is being submitted in accordance with the requirements of | |
| SMDA 1990 and 1992. | |
| Proprietary Name: | INOmax DS |
| Common Name(s): | Nitric Oxide Administration Apparatus (primary) |
| Nitric Oxide Administration Apparatus, Back-up System | |
| Nitric Oxide Analyzer | |
| Nitrogen Dioxide Analyzer | |
| Classification(s): | Class II - 21CFR868.5165, MRO |
| Class II - 21CFR868.5165, MRN (primary) | |
| Class II - 21CFR868.2380, MRP | |
| Class II - 21CFR868.2385, MRQ | |
| Panel: | Anesthesiology |
| Predicate Device(s): | Ohmeda INOvent Delivery System (now GE Healthcare) (primary) |
| 510(k) Number K974562 | |
| Datex-Ohmeda INOvent Delivery System (now GE Healthcare) | |
| 510(k) Number K000186 | |
| INO Therapeutics INOblender | |
| 510(k) Number K052663 | |
| Pulmonox Vianox Delivery System (now SensorMedics) | |
| 510(k) Number K023014 | |
| Pulmonox Aeronox Delivery System (now SensorMedics) |
510(k) Number K000653
1
| Patient Population: | The targeted patient population is neonates. This is derived from the
INOmax drug package labeling. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Clinical Setting: | The primary targeted clinical setting is the Neonatal Intensive Care Unit
(NICU) and secondary targeted clinical setting is the transport of neonates
This is derived from the INOmax drug package labeling. |
| Technology: | The technology utilized in the INOmax DS is very similar to the Datex-
Ohmeda INOvent Delivery System (now GE Healthcare), with many of |
the subsystems and components being unchanged.
| Specification | INOvent Delivery System | INOmax DS |
|---|---|---|
| Indications for | ||
| Use | Similar to INOmax DS | Except battery backup is 6 hours and provides an |
| integrated backup system for delivering a fixed flow of | ||
| NO into a constant flow of breathing circuit gas to | ||
| produce a constant concentration of NO. | ||
| Physical | ||
| Dimensions | Height 215 mm | |
| Width 350 mm | ||
| Depth 430 mm | ||
| Weight 21 Kg | Height 220 mm | |
| Width 350 mm | ||
| Depth 160 mm | ||
| Weight 5.5 Kg | ||
| Ventilator | ||
| Compatibility | Similar to INOmax DS | Except 2-60 L/min for inspiratory flow for neonatal and |
| 4-120 L/min for adult. | ||
| NO Delivery | Similar to INOmax DS | Except NO set resolution is 0.1 / 1 / 5 ppm depend on |
| range, accuracy is +/- 20% indicated or 2 ppm | ||
| whichever greater, and NO inlet pressure is 1.7 to 2.3 | ||
| Bar (25 to 33 psig). | ||
| NO Cylinder | ||
| INOmax ™ | Same as INOmax DS | Same |
| Gas Monitoring | Similar to INOmax DS | Except NO range resolution is 0 to 10ppm +/- (20% of |
| reading +0.5 ppm) 10 to 100ppm +/- (10% of reading | ||
| +0.5 ppm), calibration span is daily zero with span at | ||
| pre-use test if needed, and NO accuracy is | ||
| +/- 20% of reading +0.5 ppm. | ||
| Injector Module | Same as INOmax DS | Same |
| NO delivery | ||
| Shut Off | Same as INOmax DS | Same |
| Calibration Gas | ||
| Cylinders | NO Cal gas 40 - 80 ppm +/- 4% | |
| NO₂ Cal gas 10 -15 ppm +/- 10% | INOcal calibration gas, INO Therapeutics LLC | |
| NO Cal Gas 45 ppm +/- 4% | ||
| NO₂ Cal Gas 10 ppm +/- 10% | ||
| Electrical | ||
| Specifications | Similar to INOmax DS | Except no nurse call and battery back-up is 6 hours. |
| Environmental | ||
| Specifications | Similar to INOmax DS | Except ambient operation and storage pressure are 57 |
| to 110 kPa (430 to 825 mmHg) and | ||
| NO Back-up | ||
| Delivery | 20 ppm @ 15 L/min | 0.25 L/min when delivered into 10 L/min provides 20 |
| ppm, plus INOblender may also be used |
Material(s)
The materials selected were based upon the Datex-Ohmeda INOvent Delivery System (now GE Healthcare) and the INOblender.
2
The INOmax DS provides a constant dose of INOmax (nitric oxide) Device Description: therapy gas into the inspiratory limb of the ventilator circuit. The INOmax DS uses a "dual-channel" design to ensure the safe delivery of INOmax.
The first channel has the delivery CPU, the flow controller and the injector module to ensure the accurate delivery of NO. The second channel is the monitoring system, which includes a separate monitor CPU, the gas cells (NO, NO2, and O2 cells) and the user interface including the display and alarms. The dual-channel approach to delivery and monitoring permits INOmax delivery independent of monitoring but also allows the monitoring system to shutdown INOmax delivery if it detects a fault in the delivery system such that the NO concentration could become greater than 100 ppm. INOmax drug is stored as a gas mixture of NO/N2 in an aluminum cylinder at a nominal pressure of 2200 psig.
The cylinder is attached to a high pressure regulator which incorporates a pressure gauge that indicates cylinder pressure when the cylinder valve is open. The cylinder regulator is attached via tubing to the INOmax DS using one of the two NO/N2 quick connect inlets on the back of the machine.
The INOmax enters the back of the INOmax DS, passes through a filter. then a safety shutoff valve, which is open under normal operation.
An injector module is placed in the ventilator gas flow between the ventilator inspiratory outlet and the humidifier. Based on the ventilator flow, the INOmax cylinder concentration and set INOmax dose, the proportional solenoid delivers INOmax into the ventilator circuit via the injector module. This allows the INOmax DS to deliver a constant dose of INOmax regardless of the ventilator flow pattern or breath rate.
A flow sensor inside the INOmax DS also monitors the NO flow out of the machine. A check valve is included prior to the INOmax DS drug outlet to prevent pressure effects from the ventilator breathing circuit interfering with the NO flow sensor reading.
The INOmax DS gas monitoring system provides monitored values for inspired NO, NO2, and O2. The sample gas is withdrawn form the breathing circuit and goes through a water trap to remove excess water, a zero valve, a sample pump and finally a sample flow sensor to the gas monitoring cells. The zero valve allows the gas cells to be zeroed (during low calibration) without having to disconnect the sample line from the breathing circuit. The pump and sample flow sensor ensure a constant sample gas flow rate is maintained to the monitoring cells.
3
The gas monitoring cells are electrochemical; they are specific to each gas and provide an electronic signal, which is proportional to the concentration of the gas present.
If the delivery system does go into shut down, the INOmax DS has an integrated backup function which provides a fixed flow of INOmax (0.25L/min) into the injector module using a pneumatic on/off switch and a restrictor built into the delivery side of the system. This fixed flow of INOmax will provide 20 ppm of NO when the continuous ventilator gas flow is 10 L/min. The backup is only for short term use until a replacement delivery system can be obtained. An alarm will warn the user if the backup system is turned on while the main delivery system is in use for INOmax delivery.
The INOmax DS delivery system delivers INOmax® (nitric oxide for Indications for Use: inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. It uses a specially designed injector module, which enables tracking of the ventilator waveforms and the delivery of a synchronized and proportional dose of NO. It may be used with most ventilators.
The INOmax DS provides continuous integrated monitoring of inspired O2, NO2, and NO, and a comprehensive alarm system.
The INOmax DS incorporates a battery that provides up to 6 hours of uninterrupted NO delivery in the absence of an external power source.
The INOmax DS includes a backup NO delivery capability that provides a fixed flow of 250 mL/min of NO which along with user supplied 10 L/min of oxygen provides 20 ppm in the gas flow to a patients breathing circuit. It may also use the INOblender for backup.
The target patient population is controlled by the drug labeling for INOmax and is currently neonates. The primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU) and secondary targeted clinical setting is the transport of neonates.
4
| Testing: | The testing indicated the INOmax DS met its design input specifications,
design output specifications and risk analysis requirements. Testing
completed included:
Performance bench testing
Integrity testing
Environmental and mechanical testing
Validation against ventilators testing
Product standards certification testing |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Standard(s): | The INOmax DS was designed to comply with the applicable portions of
the following product standards |
| | 1. FDA Guidance Document for Premarket Notification Submissions
for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and
Nitrogen Dioxide Analyzer (Special Controls). |
| | 2. IEC 60601-1, plus amendments: Medical Electrical Equipment |
| | 3. IEC 60601-1-2: EMC/EMI |
| | 4. IEC 60601-1-4: Programmable Systems |
| | 5. IEC 60601-1-8: Alarms |
| | 6. CGA V-1: Medical Cylinder Connections |
| | 7. ASTM F-1462-93: Oxygen Analyzers |
| | 8. ASTM F-1054-87: Conical Fittings |
| Conclusion: | As a result of the testing of the INOmax DS, INO therapeutics deems the
device safe and effective of its indicated uses. INO Therapuetics further
deems the INOmax DS, based on testing, to be as safe and effective as the
predicate INOvent Delivery System, while performing as well or better
than this predicate device. |
5
Image /page/5/Picture/11 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three curved lines representing its wings. The eagle is positioned to the right of the text, which is arranged in a circular pattern around the logo. The text reads "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA".
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Frederick Montgomery Vice President, Medical Devices INO Therapeutics 7601-B Murphy Drive Middleton, Wisconsin 53562
DEC 1 4 2006
Re: K061901
Trade/Device Name: INO Therapeutics INOmax DS Regulation Number: 21 CFR 868,5165 Regulation Name: Nitric Oxide Administration Apparatus Regulatory Class: II Product Code: MRN, MRO, MRP and MRQ Dated: December 4, 2006 Received: December 5, 2006
Dear Mr. Montgomery:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
6
Page 2 - Mr. Montgomery
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
Ching-Lin, Ph.D.
Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
7
Indications for Use
510(k) Number (if known):
Device Name:
INO Therapeutics INOmax DS
Indications For Use:
The INOmax DS delivery system delivers INOmax® (nitric oxide of inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. It uses a specially designed injector module, which enables tracking of the ventilator wayeforms and the delivery of a synchronized and proportional dose of NO. It may be used with most ventilators.
The INOmax DS provides continuous integrated monitoring of inspired O2, NO2, and NO, and a comprehensive alarm system.
The INOmax DS incorporates a battery that provides up to 6 hours of uninterrupted NO delivery in the absence of an external power source.
The INOmax DS includes a backup NO delivery capability that provides a fixed flow of 250 mL/min of NO which along with user supplied 10 L/min of oxygen provides 20 ppm in the gas flow to a patients breathing circuit. It may also use the INOblender for backup.
The target patient population is controlled by the drug labeling for INOmax and is currently neonates. The primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU) and secondary targeted clinical setting is the transport of neonates.
Prescription Use (Part 21 CFR 801 Subpart D) and/or
Over-the-Counter-Use (Part 21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Michael Nichols 12/14/06
Page 1 of 1
195